{"id":"human-albumin-20","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypervolemia / fluid overload"},{"rate":null,"effect":"Hypertension"},{"rate":null,"effect":"Allergic reactions"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Nausea"}]},"_chembl":{"chemblId":"CHEMBL1201451","moleculeType":"Protein"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Human Albumin 20% is a hyperoncotic solution that increases plasma oncotic pressure, drawing fluid from the interstitial space into the intravascular compartment. This restores circulating blood volume and improves tissue perfusion. It is commonly used in clinical settings to manage hypovolemia, ascites, and conditions requiring rapid plasma volume expansion.","oneSentence":"Human Albumin 20% acts as a colloid osmotic agent that expands intravascular volume and maintains oncotic pressure to restore fluid balance.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:46:35.231Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypovolemia and shock management"},{"name":"Ascites in liver cirrhosis"},{"name":"Albumin replacement in hypoalbuminemia"}]},"trialDetails":[{"nctId":"NCT04476901","phase":"PHASE2","title":"Administration of Allogeneic-MSC in Patients With Non-Ischemic Dilated Cardiomyopathy","status":"RECRUITING","sponsor":"Joshua M Hare","startDate":"2021-05-07","conditions":"Non-ischemic Dilated Cardiomyopathy","enrollment":136},{"nctId":"NCT04143711","phase":"PHASE1, PHASE2","title":"Study of DF1001 in Patients With Advanced Solid Tumors","status":"COMPLETED","sponsor":"Dragonfly Therapeutics","startDate":"2019-11-11","conditions":"Solid Tumor, Adult","enrollment":270},{"nctId":"NCT05179265","phase":"PHASE1","title":"Recombinant Human Serum Albumin in Healthy Subjects","status":"COMPLETED","sponsor":"Protgen Ltd","startDate":"2021-03-29","conditions":"Hepatic Ascites","enrollment":48},{"nctId":"NCT05249374","phase":"PHASE1","title":"Recombinant Human Serum Albumin in Patients With Liver Cirrhosis and Ascites Subjects","status":"COMPLETED","sponsor":"Protgen Ltd","startDate":"2021-10-14","conditions":"Hepatic Ascites","enrollment":36},{"nctId":"NCT06553456","phase":"PHASE2, PHASE3","title":"Phase II/III Clinical Trial of Recombinant Human Serum Albumin in Cirrhotic Patients With Ascites","status":"COMPLETED","sponsor":"Protgen Ltd","startDate":"2024-08-19","conditions":"Cirrhotic Ascites","enrollment":390},{"nctId":"NCT05858853","phase":"PHASE2, PHASE3","title":"Phase II/III of Recombinant Human Serum Albumin","status":"COMPLETED","sponsor":"Protgen Ltd","startDate":"2023-05-24","conditions":"Cirrhotic Ascites","enrollment":92},{"nctId":"NCT07415655","phase":"PHASE2","title":"Modulation of Cerebral Ischemia by Albumin","status":"NOT_YET_RECRUITING","sponsor":"University Hospital Hradec Kralove","startDate":"2026-02-03","conditions":"Ischemic Stroke","enrollment":100},{"nctId":"NCT05208242","phase":"PHASE2, PHASE3","title":"Strong Albumin Solutions in Patients With Septic Shock","status":"COMPLETED","sponsor":"Manchester University NHS Foundation Trust","startDate":"2023-11-10","conditions":"Sepsis, Septic Shock, Shock, Toxic","enrollment":47},{"nctId":"NCT05056220","phase":"PHASE3","title":"Personalized Long-term Human Albumin Treatment in Patients With Decompensated Cirrhosis and Ascites","status":"RECRUITING","sponsor":"Aleksander Krag","startDate":"2024-02-26","conditions":"Decompensated Cirrhosis and Ascites","enrollment":240},{"nctId":"NCT07365475","phase":"PHASE2","title":"Efficacy and Safety of Intra-Arterial Albumin as Adjunct to Mechanical Thrombectomy in Acute Ischemic Stroke","status":"NOT_YET_RECRUITING","sponsor":"Tianjin Huanhu Hospital","startDate":"2026-01-30","conditions":"Acute Ischemic Stroke From Large Vessel Occlusion","enrollment":306},{"nctId":"NCT07294391","phase":"PHASE2","title":"The Preliminary Efficacy and Safety of Intra-Arterial Albumin as Adjunct to Mechanical Thrombectomy in Acute Ischemic Stroke","status":"NOT_YET_RECRUITING","sponsor":"Tianjin Huanhu Hospital","startDate":"2025-12-10","conditions":"Acute Ischemic Stroke From Large Vessel Occlusion","enrollment":60},{"nctId":"NCT07270874","phase":"PHASE4","title":"Study to Evaluate the Efficacy of Intravenous Administration of Human Albumin Versus Saline Solution in Patients With descompénsate Cirrhosis Grade 1B or Higher Renal Failure","status":"NOT_YET_RECRUITING","sponsor":"Fundacion Clinic per a la Recerca Biomédica","startDate":"2026-01","conditions":"Decompensated Cirrhosis, AKI - Acute Kidney Injury","enrollment":114},{"nctId":"NCT06492759","phase":"PHASE2","title":"High Dose Radiation Therapy With Pembrolizumab and Chemotherapy for the Treatment of Patients With PD-L1 Positive Metastatic Triple Negative Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Emory University","startDate":"2026-01-31","conditions":"Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma","enrollment":29},{"nctId":"NCT06535945","phase":"PHASE4","title":"Influence of Human Albumin Supplementation on Kidney Dysfunction After Liver Transplantation","status":"RECRUITING","sponsor":"Rennes University Hospital","startDate":"2025-03-26","conditions":"Liver Transplantation, Acute Kidney Injury","enrollment":400},{"nctId":"NCT07212582","phase":"PHASE3","title":"Human Albumin for Resuscitation in Surgical Septic Shock: A Randomized Controlled Trial (ALBUS Study)","status":"NOT_YET_RECRUITING","sponsor":"Mahidol University","startDate":"2025-12-01","conditions":"Critical Illness, Septic Shock","enrollment":304},{"nctId":"NCT04869397","phase":"PHASE2","title":"Treatment of Respiratory Complications Associated With COVID-19 Using Umbilical Cord Mesenchymal Stromal Cells","status":"TERMINATED","sponsor":"McGill University Health Centre/Research Institute of the McGill University Health Centre","startDate":"2021-06-14","conditions":"Covid19","enrollment":19},{"nctId":"NCT00936819","phase":"PHASE2","title":"The Enhanced Angiogenic Cell Therapy - Acute Myocardial Infarction Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ottawa Hospital Research Institute","startDate":"2013-07-19","conditions":"Anterior Wall Myocardial Infarction","enrollment":47},{"nctId":"NCT06524739","phase":"PHASE3","title":"Double-blind, Randomized, Placebo-controlled Study Evaluating Efficacy and Safety of IgPro20 in Post-COVID-19 POTS","status":"TERMINATED","sponsor":"CSL Behring","startDate":"2024-08-28","conditions":"Post-COVID Postural Orthostatic Tachycardia Syndrome","enrollment":16},{"nctId":"NCT05148286","phase":"PHASE4","title":"Albumin and Crystalloid Administration in Septic Shock","status":"RECRUITING","sponsor":"Asan Medical Center","startDate":"2022-01-17","conditions":"Septic Shock","enrollment":2426},{"nctId":"NCT03451292","phase":"PHASE3","title":"Effects of Long-Term Administration of Human Albumin in Participants With Decompensated Cirrhosis and Ascites","status":"COMPLETED","sponsor":"Grifols Therapeutics LLC","startDate":"2018-07-24","conditions":"Decompensated Cirrhosis and Ascites","enrollment":410},{"nctId":"NCT05937048","phase":"NA","title":"Coagulation Parameters With Albumin in Decompensated Cirrhosis (CoPA-D).","status":"COMPLETED","sponsor":"Institute of Liver and Biliary Sciences, India","startDate":"2023-07-30","conditions":"Decompensated Cirrhosis","enrollment":120},{"nctId":"NCT06738576","phase":"PHASE1","title":"Allogeneic Use of Expanded Mesenchymal Stem Cells Derived From Adipose Tissue (HC106), Female Urinary Incontinence Women Over 50 Years Old","status":"RECRUITING","sponsor":"Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz","startDate":"2024-12-16","conditions":"Urinary Incontinence Stress","enrollment":60},{"nctId":"NCT06911554","phase":"PHASE3","title":"A Study of Recombinant Human Albumin Injection to Treat Hypoalbuminemia in Cirrhotic Patients With Ascites","status":"COMPLETED","sponsor":"Tonghua Anrate Biopharmaceutical Co., Ltd.","startDate":"2023-06-16","conditions":"Hepatic Ascites","enrollment":416},{"nctId":"NCT05647057","phase":"NA","title":"CPB Prime Fluid Strategies to Preserve Mcirocirculatory Perfusion","status":"COMPLETED","sponsor":"Amsterdam UMC, location VUmc","startDate":"2023-07-10","conditions":"Endothelial Dysfunction, Hemolysis, Fluid Overload","enrollment":48},{"nctId":"NCT03654001","phase":"PHASE3","title":"ALBumin Italian Outcome Septic Shock-BALANCED Trial (ALBIOSS-BALANCED)","status":"COMPLETED","sponsor":"Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico","startDate":"2019-05-07","conditions":"Septic Shock","enrollment":1319},{"nctId":"NCT03169790","phase":"PHASE1, PHASE2","title":"QUILT-3.052: NANT Non-Hodgkin Lymphoma (NHL) Vaccine: Combination Immunotherapy in Subjects With Relapsed CD20-positive NHL","status":"WITHDRAWN","sponsor":"ImmunityBio, Inc.","startDate":"2017-12","conditions":"Non Hodgkin Lymphoma","enrollment":""},{"nctId":"NCT03169764","phase":"PHASE1, PHASE2","title":"QUILT-3.047: NANT Head and Neck Squamous Cell Carcinoma (HNSCC) Vaccine: Combination Immunotherapy in Subjects With HNSCC Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy","status":"WITHDRAWN","sponsor":"ImmunityBio, Inc.","startDate":"2017-12","conditions":"Head and Neck Squamous Cell Carcinoma","enrollment":""},{"nctId":"NCT03175666","phase":"PHASE1, PHASE2","title":"QUILT-3.049: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Combination Immunotherapy in Subjects With TNBC Who Have Progressed on or After Anthracycline-based Chemotherapy","status":"WITHDRAWN","sponsor":"ImmunityBio, Inc.","startDate":"2017-12","conditions":"Triple Negative Breast Cancer","enrollment":""},{"nctId":"NCT03167177","phase":"PHASE1, PHASE2","title":"QUILT-3.046: NANT Melanoma Vaccine: Combination Immunotherapy in Subjects With Melanoma Who Have Progressed On or After Chemotherapy and PD-1/PD-L1 Therapy","status":"WITHDRAWN","sponsor":"ImmunityBio, Inc.","startDate":"2017-12","conditions":"Melanoma","enrollment":""},{"nctId":"NCT03197571","phase":"PHASE1, PHASE2","title":"QUILT-3.048: NANT Urothelial Cancer Vaccine: Combination Immunotherapy in Subjects With Urothelial Cancer Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy","status":"WITHDRAWN","sponsor":"ImmunityBio, Inc.","startDate":"2017-12","conditions":"Urothelial Carcinoma","enrollment":""},{"nctId":"NCT03574649","phase":"PHASE2","title":"QUILT-2.024: Phase 2 Neoadjuvant, Consolidation, and Adjuvant Combination NANT Immunotherapy Versus Standard of Care in Subjects With Resectable Non-small Cell Lung Cancer","status":"WITHDRAWN","sponsor":"ImmunityBio, Inc.","startDate":"2018-06","conditions":"Non Small Cell Lung Cancer","enrollment":""},{"nctId":"NCT03167164","phase":"PHASE1, PHASE2","title":"QUILT-3.045: NANT Merkel Cell Carcinoma (MCC) Vaccine: Combination Immunotherapy in Subjects With MCC Who Have Progressed on or After PD-L1 Therapy","status":"WITHDRAWN","sponsor":"ImmunityBio, Inc.","startDate":"2017-12","conditions":"Merkel Cell Carcinoma","enrollment":""},{"nctId":"NCT02808182","phase":"NA","title":"Postprandial Fatty Acid Metabolism in the Natural History of Type 2 Diabetes (T2D)","status":"COMPLETED","sponsor":"Université de Sherbrooke","startDate":"2017-01-17","conditions":"Impaired Glucose Tolerance","enrollment":50},{"nctId":"NCT06681415","phase":"PHASE4","title":"Efficacy of 20% Human Albumin in Reducing Pleural Effusion After Cardiopulmonary Bypass","status":"COMPLETED","sponsor":"Pauls Stradins Clinical University Hospital","startDate":"2022-09-01","conditions":"Pleural Effusions Post Coronary Artery Bypass Graft, Hypoxia, Hypoalbuminemia","enrollment":70},{"nctId":"NCT03869385","phase":"PHASE3","title":"Albumin Replacement Therapy in Septic Shock","status":"TERMINATED","sponsor":"Jena University Hospital","startDate":"2019-10-21","conditions":"Septic Shock","enrollment":440},{"nctId":"NCT06629116","phase":"NA","title":"Study on the Role of Human Serum Albumin in Large Acute Ischemic Stroke of Anterior Circulation After Thrombectomy","status":"RECRUITING","sponsor":"Tingyu-Yi","startDate":"2024-01-30","conditions":"Cerebral Ischemia","enrollment":100},{"nctId":"NCT02673931","phase":"NA","title":"GLP-1 and Hyperoxia for Organ Protection in Heart Surgery","status":"ACTIVE_NOT_RECRUITING","sponsor":"Rigshospitalet, Denmark","startDate":"2016-02","conditions":"Coronary Disease, Shock, Cardiogenic, Renal Failure","enrollment":1400},{"nctId":"NCT06548477","phase":"NA","title":"Human Albumin for Clinical Outcome in Aneurysmal Subarachnoid Hemorrhages","status":"RECRUITING","sponsor":"Hamad Medical Corporation","startDate":"2024-08-01","conditions":"Aneurysmal Subarachnoid Hemorrhage","enrollment":84},{"nctId":"NCT06026267","phase":"NA","title":"Efficacy of Conventional Dose Protocol vs Low Dose Protocol Albumin Use in Patients With Cirrhosis and High Risk Spontaneous Bacterial Peritonitis","status":"RECRUITING","sponsor":"Institute of Liver and Biliary Sciences, India","startDate":"2023-10-10","conditions":"Liver Cirrhosis, Spontaneous Bacterial Peritonitis","enrollment":300},{"nctId":"NCT05645887","phase":"PHASE2","title":"Human Albumin Treatment in Adult Septic Shock. A Study Evaluating Immune Response and Organ Failure.","status":"WITHDRAWN","sponsor":"Albimmune SL","startDate":"2024-02","conditions":"Septic Shock","enrollment":""},{"nctId":"NCT06126354","phase":"PHASE1","title":"Dexamethasone/Pancreatic Clamp P&F","status":"WITHDRAWN","sponsor":"Columbia University","startDate":"2024-07-01","conditions":"Insulin Resistance, Prediabetic State, Non-Alcoholic Fatty Liver Disease","enrollment":""},{"nctId":"NCT02372136","phase":"NA","title":"Optimizing Individual Nutrition in Preterm Very Low Birth Weight Infants","status":"COMPLETED","sponsor":"University of Texas Southwestern Medical Center","startDate":"2016-01","conditions":"Infant, Premature, Diseases, Infant, Small for Gestational Age","enrollment":120},{"nctId":"NCT06370078","phase":"NA","title":"Effect of Early Administration of Albumin 20% Versus Crystalloid","status":"RECRUITING","sponsor":"Egymedicalpedia","startDate":"2024-06-01","conditions":"Septic Shock","enrollment":46},{"nctId":"NCT06411743","phase":"PHASE2","title":"Phase II/III of Recombinant Human Albumin Injection","status":"COMPLETED","sponsor":"The First Hospital of Jilin University","startDate":"2021-09-07","conditions":"Hepatic Ascites","enrollment":90},{"nctId":"NCT06355479","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of OsrHSA in Patients of Hepatic Cirrhosis With Hypoalbuminemia","status":"COMPLETED","sponsor":"Healthgen Biotechnology Corp.","startDate":"2023-04-10","conditions":"Hypoalbuminemia, Hepatic Cirrhosis","enrollment":328},{"nctId":"NCT05726136","phase":"PHASE4","title":"Fluid Challenge and Plasma Volume, During Surgery","status":"RECRUITING","sponsor":"Joachim Zdolsek","startDate":"2023-10-23","conditions":"Colorectal Cancer, Urologic Cancer, Gynecologic Cancer","enrollment":60},{"nctId":"NCT06202261","phase":"PHASE1, PHASE2","title":"A Study of TQB2930 for Injection Monotherapy or Combination Therapy in Patients With Recurrent/Metastatic Breast Cancer","status":"RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2023-04-13","conditions":"Metastatic Breast Cancer, Recurrent Breast Cancer, Advanced Malignancies","enrollment":154},{"nctId":"NCT06219096","phase":"NA","title":"Application of ICG@HSA Complexes in Fluorescence Image-Guided Laparoscopic Anatomical Liver Resection","status":"RECRUITING","sponsor":"West China Hospital","startDate":"2023-12-10","conditions":"Malignant Tumor of Liver, Randomized Controlled Trial","enrollment":100},{"nctId":"NCT06172387","phase":"PHASE1","title":"Intra-arterial Albumin in Acute Ischemic Stroke After Endovascular Treatment for","status":"UNKNOWN","sponsor":"Tianjin Huanhu Hospital","startDate":"2023-11-01","conditions":"Acute Ischemic Stroke","enrollment":46},{"nctId":"NCT04839991","phase":"PHASE1","title":"Study of CB307 in Patients With Advanced and/or Metastatic PSMA-positive Tumours.","status":"UNKNOWN","sponsor":"Crescendo Biologics Ltd.","startDate":"2021-06-08","conditions":"Advanced and/or Metastatic Solid Tumours","enrollment":70},{"nctId":"NCT01531803","phase":"PHASE4","title":"Safety Study of Kedbumin 25% Versus Normal Saline in the Treatment of Post-Surgical Hypovolemia in Pediatric Patients","status":"TERMINATED","sponsor":"Kedrion S.p.A.","startDate":"2015-02-05","conditions":"Hypovolemia","enrollment":3},{"nctId":"NCT06111261","phase":"NA","title":"Initial Resuscitation With Albumin in Hemorrhagic Shock to Reduce Positive Fluid Balance","status":"UNKNOWN","sponsor":"Seoul National University Hospital","startDate":"2023-11-15","conditions":"Bleeding, Massive Hemorrhage, Massive Transfusion Protocol","enrollment":36},{"nctId":"NCT04517695","phase":"","title":"Blood Volume Assessment in COVID-19 and Bacterial Sepsis","status":"COMPLETED","sponsor":"NYU Langone Health","startDate":"2020-08-01","conditions":"Covid19, Acute Respiratory Distress Syndrome, Bacterial Sepsis","enrollment":39},{"nctId":"NCT03818737","phase":"PHASE3","title":"Multicenter Trial of Stem Cell Therapy for Osteoarthritis (MILES)","status":"COMPLETED","sponsor":"Emory University","startDate":"2019-03-28","conditions":"Osteoarthritis","enrollment":475},{"nctId":"NCT05647200","phase":"NA","title":"Optimization of Prime Fluid Strategy to Preserve Microcirculatory Perfusion During Cardiac Surgery With Cardiopulmonary Bypass, Part II","status":"UNKNOWN","sponsor":"Amsterdam UMC, location VUmc","startDate":"2023-10-15","conditions":"Endothelial Dysfunction, Hemolysis, Fluid Overload","enrollment":64},{"nctId":"NCT02837094","phase":"PHASE1","title":"Enhanced Epidermal Antigen Specific Immunotherapy Trial -1","status":"COMPLETED","sponsor":"Cardiff University","startDate":"2016-09-29","conditions":"Type 1 Diabetes","enrollment":6},{"nctId":"NCT02587572","phase":"PHASE2","title":"Safety and Efficacy Trial Using Allogeneic Human Mesenchymal Stem Cells: The SIRONA Trial","status":"WITHDRAWN","sponsor":"Longeveron Inc.","startDate":"2023-12-01","conditions":"Metabolic Disease, Endothelial Dysfunction","enrollment":""},{"nctId":"NCT04071041","phase":"PHASE3","title":"Effect of Albumin Administration in Hypoalbuminemic Hospitalized Patients With Community-acquired Pneumonia.","status":"TERMINATED","sponsor":"Jordi Carratala","startDate":"2019-10-31","conditions":"Community-acquired Pneumonia, Hypoalbuminemia","enrollment":39},{"nctId":"NCT02097121","phase":"PHASE3","title":"OnabotulinumtoxinA for the Treatment of Urinary Incontinence Due to Overactive Bladder in Pediatric Patients (12 to 17)","status":"TERMINATED","sponsor":"Allergan","startDate":"2014-05-23","conditions":"Urinary Incontinence, Urinary Bladder, Overactive","enrollment":56},{"nctId":"NCT01436292","phase":"PHASE4","title":"Hypoalbuminemia in Burn Patients","status":"WITHDRAWN","sponsor":"Centre hospitalier de l'Université de Montréal (CHUM)","startDate":"2011-09","conditions":"Second or Third Degree Burns","enrollment":""},{"nctId":"NCT05596942","phase":"PHASE3","title":"Evaluating the Efficacy of Channa Striata in Stabilizing eNOS in Patients With Septic.","status":"COMPLETED","sponsor":"Universitas Sebelas Maret","startDate":"2021-07-01","conditions":"Sepsis","enrollment":42},{"nctId":"NCT05240391","phase":"PHASE3","title":"Midodrine Versus Albumin for Prevention of Paracentesis Induced Circulatory Disturbance","status":"COMPLETED","sponsor":"Asian Institute of Gastroenterology, India","startDate":"2021-02-20","conditions":"Paracentesis-Induced Circulatory Dysfunction","enrollment":50},{"nctId":"NCT02059681","phase":"PHASE1","title":"Phase I Trial of Endocavitary Injection of Bone Marrow Derived CD133+ Cells in Ischemic Refractory Cardiomyopathy (RECARDIO Trial)","status":"COMPLETED","sponsor":"Centro Cardiologico Monzino","startDate":"2013-12","conditions":"Chronic Myocardial Ischemia","enrollment":12},{"nctId":"NCT04437810","phase":"NA","title":"To Study Efficacy of Albumin in Cirrhosis With Spontaneous Bacterial Peritonitis at Low Risk for AKI Development","status":"UNKNOWN","sponsor":"Institute of Liver and Biliary Sciences, India","startDate":"2020-07-08","conditions":"Liver Cirrhosis, Acute Kidney Injury","enrollment":100},{"nctId":"NCT05214872","phase":"","title":"The Impact of Selected Factors on the Cardiovascular System in Chronic Kidney Disease","status":"COMPLETED","sponsor":"Poznan University of Medical Sciences","startDate":"2016-03-25","conditions":"Atherosclerosis of Artery, Inflammation, Chronic Kidney Diseases","enrollment":252},{"nctId":"NCT02600130","phase":"PHASE1","title":"Lomecel-B Infusion Versus Placebo in Patients With Alzheimer's Disease","status":"COMPLETED","sponsor":"Longeveron Inc.","startDate":"2016-10-10","conditions":"Alzheimer's Disease","enrollment":33},{"nctId":"NCT04835480","phase":"PHASE2","title":"A Phase II Study of OsrHSA in Patients With Decompensated Cirrhotic Ascites","status":"RECRUITING","sponsor":"Healthgen Biotechnology Corp.","startDate":"2021-03-22","conditions":"Cirrhotic Ascites","enrollment":220},{"nctId":"NCT05080543","phase":"PHASE1","title":"Microcirculation Recruitment Using Albumin 20% and Terlipressin in Septic Patients","status":"UNKNOWN","sponsor":"Amany Mousa Salama Muhammed","startDate":"2021-10","conditions":"Septic Shock","enrollment":36},{"nctId":"NCT02755155","phase":"PHASE4","title":"Optimization of Therapeutic Human Serum Albumin Infusion in Selected Critically Ill Patients","status":"TERMINATED","sponsor":"University Hospital, Strasbourg, France","startDate":"2016-09","conditions":"Shock, Systemic Inflammatory Response Syndrome (SIRS), Hypoalbuminaemia","enrollment":138},{"nctId":"NCT05033704","phase":"NA","title":"Effect of Human Plasma Protein Transfusion With and Without Crystalloids During Major Liver Resection Surgeries","status":"UNKNOWN","sponsor":"Hamad Medical Corporation","startDate":"2019-09-09","conditions":"Coagulation; Intravascular, Fluid Electrolyte Disorders","enrollment":48},{"nctId":"NCT03167645","phase":"PHASE4","title":"SUbstition of PERioperative Albumin Deficiency Disorders","status":"COMPLETED","sponsor":"Technical University of Munich","startDate":"2017-06-19","conditions":"Hypoalbuminemia","enrollment":600},{"nctId":"NCT04243382","phase":"PHASE2","title":"Treatment of Children With Autistic Spectrum Disorder With Autologous Umbilical Cord Blood, a Pilot Study","status":"UNKNOWN","sponsor":"Sheba Medical Center","startDate":"2020-02-27","conditions":"Autistic Spectrum Disorder","enrollment":60},{"nctId":"NCT04243408","phase":"PHASE2","title":"Treatment of Children With Cerebral Palsy With Autologous Umbilical Cord Blood, a Pilot Study","status":"UNKNOWN","sponsor":"Sheba Medical Center","startDate":"2020-07-08","conditions":"Cerebral Palsy","enrollment":72},{"nctId":"NCT02956122","phase":"PHASE2, PHASE3","title":"A Phase 2/3 Study of GLASSIA for the Treatment of Acute GvHD","status":"TERMINATED","sponsor":"Baxalta now part of Shire","startDate":"2017-04-26","conditions":"Graft Versus Host Disease","enrollment":1},{"nctId":"NCT02820844","phase":"PHASE3","title":"Efficacy and Safety of GSK1358820 in Subjects With Overactive Bladder","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2016-08-10","conditions":"Urinary Bladder, Overactive","enrollment":250},{"nctId":"NCT02560519","phase":"PHASE4","title":"Albumin in Cardiac Surgery","status":"COMPLETED","sponsor":"Helsinki University Central Hospital","startDate":"2017-03-21","conditions":"C.Surgical Procedure; Cardiac","enrollment":1386},{"nctId":"NCT02509156","phase":"PHASE1","title":"Stem Cell Injection in Cancer Survivors","status":"COMPLETED","sponsor":"The University of Texas Health Science Center, Houston","startDate":"2016-08","conditions":"Cardiomyopathy Due to Anthracyclines","enrollment":46},{"nctId":"NCT02479802","phase":"PHASE2","title":"Efficacy and Safety of Plasma Exchange With Albumin in Patients With Amyotrophic Lateral Sclerosis","status":"COMPLETED","sponsor":"Instituto Grifols, S.A.","startDate":"2014-11","conditions":"Amyotrophic Lateral Sclerosis","enrollment":13},{"nctId":"NCT03754400","phase":"NA","title":"Efficacy of Albumin Therapy With Standard Medical Treatment (SMT) as Compared to Standard Medical Treatment (SMT) in Improving Patient Survival and Immune Modulation in Patients With Acute on Chronic Liver Failure (ASIA Trial).","status":"UNKNOWN","sponsor":"Institute of Liver and Biliary Sciences, India","startDate":"2018-09-10","conditions":"Acute on Chronic Liver Failure","enrollment":200},{"nctId":"NCT00140140","phase":"PHASE1, PHASE2","title":"A Phase I/II Study of ABI-007 (Abraxane®, Nab®-Paclitaxel)and Vinorelbine in Patients With Stage IV (Metastatic) Breast Cancer","status":"TERMINATED","sponsor":"Celgene","startDate":"2005-08","conditions":"Stage IV (Metastatic) Breast Cancer","enrollment":16},{"nctId":"NCT04058613","phase":"NA","title":"Effects of Maintaining Steady Albumin Levels (TAT 4) on Survival and Liver Related Complications in Cirrhosis With Ascites","status":"UNKNOWN","sponsor":"Institute of Liver and Biliary Sciences, India","startDate":"2019-09-10","conditions":"Liver Cirrhosis","enrollment":304},{"nctId":"NCT00587990","phase":"PHASE1, PHASE2","title":"Prospective Randomized Study of Mesenchymal Stem Cell Therapy in Patients Undergoing Cardiac Surgery (PROMETHEUS)","status":"TERMINATED","sponsor":"Joshua M Hare","startDate":"2007-11","conditions":"Stem Cell Transplantation, Ventricular Dysfunction, Left","enrollment":9},{"nctId":"NCT01822600","phase":"PHASE4","title":"The Therapeutic Role of Intravenous Albumin Administration for Peptic Ulcer Bleeding Patients With Hypoalbuminemia","status":"COMPLETED","sponsor":"National Cheng-Kung University Hospital","startDate":"2010-01","conditions":"Peptic Ulcer Bleeding, Hypoalbuminemia","enrollment":91},{"nctId":"NCT01561053","phase":"PHASE2, PHASE3","title":"A Study to Evaluate Albumin and Immunoglobulin in Alzheimer's Disease","status":"COMPLETED","sponsor":"Instituto Grifols, S.A.","startDate":"2012-04-19","conditions":"Alzheimer's Disease","enrollment":347},{"nctId":"NCT00968695","phase":"PHASE4","title":"Effects of Long Term Albumin 20% Administration in Patients With Cirrhosis and Ascites.","status":"COMPLETED","sponsor":"Instituto Grifols, S.A.","startDate":"2009-07","conditions":"Cirrhosis, Ascites","enrollment":33},{"nctId":"NCT03950778","phase":"EARLY_PHASE1","title":"The Effect of Albumin Supplementation on the Inflammatory and Oxidative Stress Markers in Septic Patients","status":"UNKNOWN","sponsor":"University of Pecs","startDate":"2019-04-01","conditions":"Albumin Supplementation, Albumin Therapy, Sepsis","enrollment":30},{"nctId":"NCT01973660","phase":"PHASE2","title":"PAM50 HER2-enriched Phenotype as a Predictor of Response to Dual HER2 Blockade in HER2-positive Early Breast Cancer","status":"COMPLETED","sponsor":"SOLTI Breast Cancer Research Group","startDate":"2013-10","conditions":"Breast Cancer","enrollment":151},{"nctId":"NCT01545076","phase":"PHASE3","title":"Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Treatment With Subcutaneous Immunoglobulin (IgPro20)","status":"COMPLETED","sponsor":"CSL Behring","startDate":"2012-03","conditions":"Chronic Inflammatory Demyelinating Polyneuropathy, Polyradiculoneuropathy","enrollment":208},{"nctId":"NCT02556580","phase":"PHASE4","title":"Volume Kinetics for 20% Albumin in Different Clinical Situations","status":"UNKNOWN","sponsor":"Sodertalje Hospital","startDate":"2016-02","conditions":"Unconscious, Inflammation","enrollment":45},{"nctId":"NCT02442791","phase":"NA","title":"GLP-1 Analogs for Neuroprotection After Cardiac Arrest","status":"COMPLETED","sponsor":"Jesper Kjaergaard","startDate":"2014-06","conditions":"Cardiac Arrest, Coma","enrollment":120},{"nctId":"NCT03274791","phase":"","title":"Clinical Features and Airways Inflammation in Never Smokers and Smokers With COPD","status":"COMPLETED","sponsor":"Ministry of Scientific Research, Tunisia","startDate":"2013-09","conditions":"COPD, Airway Obstruction, Inflammation","enrollment":68},{"nctId":"NCT02479581","phase":"PHASE2","title":"The Safety and Efficacy of the Enhanced Recovery After Surgery(ERAS)Applied on Cardiac Surgery With Cardiopulmonary Bypass","status":"COMPLETED","sponsor":"Xiangya Hospital of Central South University","startDate":"2015-07","conditions":"Valvular Heart Disease","enrollment":226},{"nctId":"NCT03084809","phase":"PHASE4","title":"Chemotherapy Combined With CIK Treating Colon Cancer","status":"COMPLETED","sponsor":"China Meitan General Hospital","startDate":"2012-05-06","conditions":"Colorectal Cancer, Cytokine-induced Killer Cells, Postoperative Complications","enrollment":46},{"nctId":"NCT01288794","phase":"PHASE4","title":"Human Albumin for the Treatment of Ascites in Patients With Hepatic Cirrhosis","status":"COMPLETED","sponsor":"University of Bologna","startDate":"2011-03","conditions":"Liver Cirrhosis, Ascites","enrollment":431},{"nctId":"NCT01050114","phase":"PHASE3","title":"OnabotulinumtoxinA (onaBoNT-A) Versus Oral Oxybutynin ER","status":"UNKNOWN","sponsor":"Christopher Patrick Smith","startDate":"2013-08","conditions":"Overactive Bladder","enrollment":36},{"nctId":"NCT00220779","phase":"PHASE2","title":"Immune Globulin Intravenous (IGIV) To Treat Relapsing, Remitting Multiple Sclerosis","status":"COMPLETED","sponsor":"Grifols Therapeutics LLC","startDate":"2002-12","conditions":"Multiple Sclerosis, Relapsing-Remitting","enrollment":128},{"nctId":"NCT02203968","phase":"PHASE1, PHASE2","title":"Fibrinogen in the Initial Resuscitation of Severe Trauma (FiiRST)","status":"COMPLETED","sponsor":"Sunnybrook Health Sciences Centre","startDate":"2014-10","conditions":"Trauma, Injury, Bleeding","enrollment":50},{"nctId":"NCT00220740","phase":"PHASE3","title":"Immune Globulin Intravenous (IGIV) For Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)","status":"COMPLETED","sponsor":"Grifols Therapeutics LLC","startDate":"2004-04","conditions":"Polyradiculoneuropathy, Chronic Inflammatory Demyelinating","enrollment":117},{"nctId":"NCT00220805","phase":"PHASE2","title":"Use of Immune Globulin Intravenous (Human) To Treat Age-Related Macular Degeneration","status":"COMPLETED","sponsor":"Grifols Therapeutics LLC","startDate":"2004-01","conditions":"Macular Degeneration","enrollment":96},{"nctId":"NCT02167087","phase":"NA","title":"Sentinel Node Mapping With Indocyanine Green in Colon Cancer: a Feasibility Trial and a Descriptive Serie.","status":"COMPLETED","sponsor":"Ismail Gögenür","startDate":"2015-03","conditions":"Colon Cancer, Lymphatic Metastasis","enrollment":30}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":19,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Human Albumin 20%","genericName":"Human Albumin 20%","companyName":"Asian Institute of Gastroenterology, India","companyId":"asian-institute-of-gastroenterology-india","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Human Albumin 20% acts as a colloid osmotic agent that expands intravascular volume and maintains oncotic pressure to restore fluid balance. Used for Hypovolemia and shock management, Ascites in liver cirrhosis, Albumin replacement in hypoalbuminemia.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}